GNC Publishes Groundbreaking GLP-1 Supplement Review to Guide Clinicians to Support GLP-1 Consumers
PITTSBURGH, Pa., Oct. 30, 2025 /PRNewswire/ — GNC, the global leader in health and wellness, announced the publication of a new peer-reviewed journal article, “Dietary Supplement Considerations During Glucagon-like Peptide-1 Receptor Agonist Treatment: A Narrative Review,” in Obesity…
Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine
Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially been surpassed by Eli Lilly. Lilly’s tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, brought in $10.1 billion in sales in the third quarter, the pharma giant said Thursday. Merck, meanwhile, reported […]
US weight-loss drugs drive drop in obesity levels
Obesity levels in the US are falling, driven by the increased use of GLP-1 weight-loss drugs such as Ozempic. The US has some of the highest obesity rates in the world, and the percentage of Americans with BMI over 30 — the classification for obesity — peaked at 39.9% in 2022, but has now fallen […]
STAT+: Novo Nordisk makes offer for obesity-focused Metsera, aiming to outbid Pfizer
A bidding war has broken into the open for obesity-focused Metsera, with Novo Nordisk on Thursday saying it had made an offer for the biotech, a month after Pfizer announced its plan to purchase the firm. The Novo offer, what it called “an unsolicited proposal,” reflects the pressure pharma companies are under to gain an […]
Danone’s playbook in the GLP-1 arena: 3 key moves
Danone is expanding into GLP-1 nutrition with dairy, microbiome solutions, and plant-based shakes. Three key moves shaping its strategy.
China“s Innovent drug outperforms Novo“s semaglutide in diabetes trial
2025.10.30 by CHEN Yang China’s Innovent Biologics said its dual receptor agonist Mastutide delivered stronger results than Novo Nordisk’s semaglutide (Ozempic) in a Phase III trial among Chinese patients with type 2 diabetes and obesity, signaling how Chinese drugmakers are narrowing the gap in the global obesity-drug race. After 32 weeks, 48 percent of patients […]
WHO reviews highlight limited long-term data on GLP-1 drug safety
Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity.
Diabetes remission possible with GLP-1 drugs, Italian study confirms
In a large real-world Italian cohort, GLP-1 receptor agonist therapy led to measurable rates of type 2 diabetes remission, depending on how remission was defined. The most pragmatic definition (Remission 3) was linked to improved glycemia, weight, and a lower risk of microvascular and cardiovascular events.
Eli Lilly partners with Walmart to sell weight-loss drug directly to patients nationwide
Patients will be able to access Eli Lilly’s weight-loss drug Zepbound at Walmart pharmacies nationwide through its direct-to-consumer program as soon as next month. The partnership between Eli Lilly and Company and Walmart, announced Wednesday, will allow people with a valid prescription to pick up single-dose vials of Zepbound at Walmart pharmacies nationwide or opt […]
GLP-1 drugs effective for weight loss, but more independent studies needed
Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity.